Mangoceuticals Inc (MGRX)

NASD · Healthcare · Health Information Services · USA

Mangoceuticals Inc is a micro cap company (market value under $300 million) in the Health Information Services industry.

Mangoceuticals connects consumers to licensed healthcare professionals through its telemedicine platform at MangoRX.com to provide care and men's wellness products. The company develops and markets compounded products under brands including Mango for erectile dysfunction, Grow for hair loss, Mojo for hormone balance, and Slim for weight management. All compounded products are produced by a related-party pharmacy and require physician prescriptions.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Mangoceuticals Inc stock.

Our verdict on MGRX

Overvalued: intrinsic value $0.03 per share, market price $0.16, margin of safety -440.4% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $0.03; the price of $0.16 is 440% above that value.

ETFs with the most weight in MGRX

More on MGRX

Browse

Peers in Health Information Services

All 40 Health Information Services stocks

Cheaper than MGRX in Health Information Services

10 more in this industry show a wider margin of safety.

Is MGRX undervalued or overvalued?

MGRX is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $0.03; the price of $0.16 is 440% above that value.

What is the intrinsic value of MGRX?

$0.03 per share (as of the 2026-11-17 close), against a market price of $0.16. That is a margin of safety of -440.4%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.